What's Happening?
Sanofi has become the market authorization holder for Nuvaxovid, a non-mRNA COVID-19 vaccine, in Canada. This transition from Novavax to Sanofi is part of a strategic agreement signed in May 2024. Nuvaxovid, a protein-based vaccine, will be available
for the 2026-2027 season, offering Canadians an alternative to mRNA vaccines. The vaccine has shown approximately 90% efficacy in preventing symptomatic COVID-19 and is suitable for individuals aged 12 and older. Sanofi's move underscores its commitment to diversifying vaccine options and addressing respiratory diseases in Canada.
Why It's Important?
The introduction of Nuvaxovid by Sanofi provides Canadians with more vaccine choices, potentially increasing vaccine uptake and addressing vaccine hesitancy. This is crucial as COVID-19 continues to pose significant health risks, with high numbers of cases and hospitalizations reported in previous seasons. By offering a non-mRNA option, Sanofi caters to those who prefer traditional vaccine technologies, which may improve public confidence and reduce the healthcare burden. This development also highlights Sanofi's role in the global vaccine market and its investment in public health.
What's Next?
Sanofi is preparing to meet the anticipated demand for Nuvaxovid in Canada, ensuring distribution and safety monitoring. The company is working with provincial authorities to confirm availability across regions. As the 2026-2027 respiratory virus season approaches, Sanofi's efforts will focus on expanding its respiratory vaccine offerings and maintaining its position as a leading biopharma manufacturer in Canada.
